Peptides News and Research

RSS

Zyomyx issued five new biotech patents

Zyomyx a privately held biotechnology company, has announced that the United States Patent and Trademark Office issued five new patents to the Company. With these additions, Zyomyx has further strengthened its proprietary position in the area of protein biochip technology development and commercialization.

6 Aug 2004

A new marker for osteoarthritis

Osteoarthritis (OA) is a common, crippling age-related disease characterized by the gradual destruction of cartilage cushioning the joints.

5 Aug 2004

FDA has granted orphan drug designation to Myogen's ambrisentan, for the treatment of pulmonary arterial hypertension

Myogen has announced that the United States Food and Drug Administration has granted orphan drug designation to ambrisentan for the treatment of pulmonary arterial hypertension (PAH).

3 Aug 2004

Switches in the brain that tell the body to stop eating and start burning calories

A Brown-led research team has discovered a pair of universal switches in the brain that tell the body to stop eating and start burning calories.

3 Aug 2004

Hormone previously identified in the venom of the green mamba snake may play role in stroke research

A Mayo Clinic research team is focusing on a hormone previously identified in the venom of the green mamba snake for the role it may play in a dangerous blood vessel narrowing in stroke patients that can lead to a second stroke, reduced blood flow and brain damage.

2 Aug 2004

New method for detecting premature birth

Researchers at Oregon Health & Science University have discovered a method for detecting intra-amniotic infections in pregnant women using state-of-the-art methods.

29 Jul 2004

Leptin's fat-burning role in humans

For nearly a decade, scientists have known that leptin plays an important fat-burning role in humans. But the map of leptin's path through the body – the key to understanding how and why the hormone works – is still incomplete.

27 Jul 2004

Several key findings from clinical trial of an investigational Alzheimer's disease treatment

Elan Corporation and Wyeth Pharmaceuticals have announced several key findings from their Phase IIa clinical trial of an investigational Alzheimer's disease (AD) treatment, AN-1792, which were presented in Philadelphia at the 9th International Conference on Alzheimer's Disease and Related Disorders.

22 Jul 2004

Natural organohalogens have potent anticancer and antibacterial activity

Human made chemical compounds called organohalogens get loads of attention as they are best known for their often harmful effect on the environment - substances like the CFCs (the ozone-damaging chemicals), dioxin (found in the herbicide Agent Orange), PCBs (industrial fluids) and several pesticides.

22 Jul 2004

Scientists determine structure of staph, anthrax enzyme

Researchers at the U.S. Department of Energy's Argonne National Laboratory and the University of Chicago have determined the crystal structure of sortase B, an enzyme found in the bacteria that cause staph and anthrax. While an antibiotic is probably five to seven years away, the structure could provide the first clue in developing a treatment for the infections.

15 Jul 2004

Targeted therapeutics capable of preventing or limiting the metastasis of skin cancer

An international team of scientists has identified an important molecular link involved in the spread – or metastasis – of melanoma to other organs such as the lungs.

15 Jul 2004

Research that directs cancer-killing immune cells against the deadliest brain tumors shows promise

Researchers seeking to direct cancer-killing immune cells against the deadliest brain tumors have three new targets that show promise in laboratory studies and in a Phase I patient trial, according to two articles in the July 15 issue of the journal Cancer Research.

15 Jul 2004

New research offers clues into how the body controls appetite and food intake

Concurrent with the national obesity epidemic has been a rise in the discoveries about how the body controls appetite and food intake.

30 Jun 2004

Delphi expands medical footprint

Delphi Medical Systems Corporation, a subsidiary of Delphi Corporation, recently signed a licensing agreement with Switzerland-based medical device company Debiotech, S.A.

29 Jun 2004

Treating cocaine addiction with a virus

Scientists at The Scripps Research Institute have designed a potentially valuable tool for treating cocaine addiction by creating a modified "phage" virus that soaks up the drug inside the brain.

24 Jun 2004

New patent for screening technology

MorphoSys AG announced today that the U.S. Patent & Trademark Office has granted a new patent on its proprietary CysDisplay™ screening technology.

24 Jun 2004

Research on the potential oral delivery of a current intravenous cancer drug using polymeric nano-delivery systems technology

Labopharm Inc. today announced that it has entered into an agreement with Debiopharm S.A. under which Debiopharm has engaged Labopharm to conduct research on the potential oral delivery of a current intravenous cancer drug using Labopharm’s proprietary polymeric nano-delivery systems technology (also referred to as micelles technology).

16 Jun 2004

Project aimed at eliminating anthrax as a potential weapon for terrorists

La Trobe University scientists are using their own unique peptide 'library' containing a thousand million molecular sequences in a project aimed at eliminating anthrax as a potential weapon for terrorists.

10 Jun 2004

Australian scientists have developed a tool that acts as a pregnancy test for the detection of anthrax

Once a deadly disease associated with animals, anthrax is now used as a bioterrorist weapon. While infection can be controlled with antibiotics, in a bioterrorism attack people will not know they have been infected until symptoms develop, at which stage drugs are useless.

7 Jun 2004

BioSante publishes oral insulin study

BioSante Pharmaceuticals, Inc. has announced the publication of positive results of a preclinical study of its proprietary calcium phosphate nanoparticle (CAP) delivery system for the oral delivery of insulin in the June 11 issue of the peer-reviewed International Journal of Pharmaceutics.

2 Jun 2004

Peptides News and Research

Zyomyx issued five new biotech patents

A new marker for osteoarthritis

FDA has granted orphan drug designation to Myogen's ambrisentan, for the treatment of pulmonary arterial hypertension

Switches in the brain that tell the body to stop eating and start burning calories

Hormone previously identified in the venom of the green mamba snake may play role in stroke research

New method for detecting premature birth

Leptin's fat-burning role in humans

Several key findings from clinical trial of an investigational Alzheimer's disease treatment

Natural organohalogens have potent anticancer and antibacterial activity

Scientists determine structure of staph, anthrax enzyme

Targeted therapeutics capable of preventing or limiting the metastasis of skin cancer

Research that directs cancer-killing immune cells against the deadliest brain tumors shows promise

New research offers clues into how the body controls appetite and food intake

Delphi expands medical footprint

Treating cocaine addiction with a virus

New patent for screening technology

Research on the potential oral delivery of a current intravenous cancer drug using polymeric nano-delivery systems technology

Project aimed at eliminating anthrax as a potential weapon for terrorists

Australian scientists have developed a tool that acts as a pregnancy test for the detection of anthrax

BioSante publishes oral insulin study

Exploring the intersection of biology and proteomics

Unlocking the Secrets of Multiple Sclerosis Progression: Brain-Immune Cell Communication

Passing on Polycystic Ovary Syndrome: Health risks for male offspring of women with PCOS

Latest News